01 14Cymbalta
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2019 Revenue in Millions : 239
2018 Revenue in Millions : 222
Growth (%) : 8
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2020 Revenue in Millions : 768
2019 Revenue in Millions : 725
Growth (%) : 6
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2020 Revenue in Millions : 251
2019 Revenue in Millions : 244
Growth (%) : 3
Main Therapeutic Indication : Neurology
Currency : USD
2021 Revenue in Millions : 582
2020 Revenue in Millions : 768
Growth (%) : -24
Main Therapeutic Indication : Neurology
Currency : USD
2021 Revenue in Millions : 171
2020 Revenue in Millions : 241
Growth (%) : -24
Main Therapeutic Indication : Neurology
Currency : USD
2022 Revenue in Millions : 283
2021 Revenue in Millions : 582
Growth (%) : -51
Main Therapeutic Indication : Neurology
Currency : USD
2022 Revenue in Millions : 48
2021 Revenue in Millions : 170
Growth (%) : -72
Main Therapeutic Indication : Neurology
Currency : USD
2023 Revenue in Millions : 28
2022 Revenue in Millions : 48
Growth (%) : -34
Main Therapeutic Indication : Neuroscience and Mental Health
Currency : USD
2015 Revenue in Millions : 1,615
2014 Revenue in Millions : 1,028
Growth (%) : -36%
Main Therapeutic Indication : Neuroscience/Mental Health
Currency : USD
2014 Revenue in Millions : -68.20%
2013 Revenue in Millions :
Growth (%) :
LOOKING FOR A SUPPLIER?